Suppr超能文献

根据 HIV-1 核心受体嗜性,诊断时 CD4+ 细胞计数 >350 或 >500 个/毫米 3 的患者中 CD4+ 细胞计数的自然演变。

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500  cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism.

机构信息

UMR S-943, Pierre et Marie Curie University, Paris, France.

出版信息

J Med Virol. 2012 Dec;84(12):1853-6. doi: 10.1002/jmv.23362.

Abstract

The HIV-1 coreceptor usage may play a critical role in AIDS pathogenesis and the X4-using viruses are considered to be more pathogenic than the R5-tropic viruses. These observations may influence the therapeutic decisions by asking for an earlier antiretroviral (ARV) treatment for the patients infected by the X4-tropic viruses compared with those infected by the R5-tropic viruses. The natural evolution of CD4+ cell count for 109 non-treated patients infected by the R5- or X4-tropic HIV-1 viruses with CD4+ >350 and >500 cells/mm(3) at time of diagnosis was compared until the initiation of an ARV regimen. The coreceptor usage was determined from the V3 env region sequence by Geno2Pheno (false positive rate 10%). A mixed linear regression model to analyse the CD4+ data with tropism as fixed effect in the model was used. Overall, 93 (85.3%) and 16 (14.7%) were infected by R5- and X4-tropic viruses, respectively. The median age, baseline CD4+ cell count, and viral load were 34 years (IQR: 30-42), 523 cells/mm(3) (IQR: 420-604), and 4.5 log(10)  copies/ml (IQR: 3.9-5.0), respectively. There was no statistical difference in time to progression between the patients harboring R5- or X4-tropic viruses. The same results were observed for the sub-group of patients with CD4+ cell count >500 cells/mm(3). The virus tropism has no impact on the CD4+ cell count evolution in these HIV-1 patients diagnosed with CD4+ >350 or >500 cells/mm(3) suggesting that the tropism determination at time of diagnosis does not seem to be a useful tool to predict the clinical progression.

摘要

HIV-1 核心受体的使用可能在艾滋病发病机制中起关键作用,并且 X4 使用的病毒被认为比 R5 嗜性病毒更具致病性。这些观察结果可能会影响治疗决策,要求对感染 X4 嗜性病毒的患者比感染 R5 嗜性病毒的患者更早开始抗逆转录病毒 (ARV) 治疗。

比较了 109 例未接受治疗的患者,这些患者在诊断时 CD4+>350 和 CD4+>500 个细胞/mm(3)时,感染了 R5 或 X4 嗜性 HIV-1 病毒,比较了其自然 CD4+细胞计数的演变,直到开始 ARV 治疗方案。核心受体的使用通过 Geno2Pheno 从 V3 env 区序列确定(假阳性率为 10%)。使用混合线性回归模型分析带有嗜性的 CD4+数据作为模型中的固定效应。

总体而言,93 例(85.3%)和 16 例(14.7%)分别感染了 R5 和 X4 嗜性病毒。中位年龄、基线 CD4+细胞计数和病毒载量分别为 34 岁(IQR:30-42)、523 个细胞/mm(3)(IQR:420-604)和 4.5 log(10) 拷贝/ml(IQR:3.9-5.0)。携带 R5 或 X4 嗜性病毒的患者在进展时间上无统计学差异。对于 CD4+细胞计数>500 个细胞/mm(3)的患者亚组,也观察到了相同的结果。在这些诊断时 CD4+>350 或 CD4+>500 个细胞/mm(3)的 HIV-1 患者中,病毒嗜性对 CD4+细胞计数的演变没有影响,表明诊断时确定嗜性似乎不是预测临床进展的有用工具。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验